PMID: 3973064Jan 1, 1985

Studies with stable isotopes II: Phenobarbital pharmacokinetics during monotherapy

Journal of Clinical Pharmacology
T R BrowneD J Greenblatt


Six healthy adults receiving no other medications were given tracer doses of 90 mg of stable isotope-labeled phenobarbital (PB) intravenously before, and four weeks after, and 12 weeks after beginning therapy. Serum samples were collected for 96 hours after each injection, and the concentration of stable isotope-labeled PB in each sample was determined by gas chromatographic mass spectrometry. The volume of distribution, elimination half-life, and total clearance of PB did not differ significantly on any of the three occasions measured. Phenobarbital clearance did not correlate significantly with total PB serum concentration. Clearances determined from single-dose studies before beginning PB therapy accurately predicted steady-state PB serum concentrations. Therefore, it is not necessary to adjust PB dosage for time-dependent or dose-dependent changes in clearance during monotherapy. In addition, clearance or serum concentration determined at one dosing rate directly predicts serum concentration at another dosing rate.


May 1, 1979·Journal of Clinical Pharmacology·C T ViswanathanP G Welling
Feb 1, 1978·Journal of Clinical Pharmacology·C T ViswanathanP G Welling
Jan 1, 1977·Antimicrobial Agents and Chemotherapy·D A SpykerW M O'Brien
Sep 1, 1977·Toxicology and Applied Pharmacology·G D DiVincenzoJ Dedinas
Jan 1, 1985·Journal of Clinical Pharmacology·T R BrowneD J Greenblatt
Jul 6, 1971·Annals of the New York Academy of Sciences·P L MorselliS Garattini
Dec 1, 1969·The Journal of Clinical Investigation·E S Vesell, J G Page
Jan 1, 1969·Acta Pharmacologica Et Toxicologica·A Ravn-JonsenO Secher
Jul 1, 1982·Journal of Clinical Pharmacology·T R BrowneD J Greenblatt
Jan 1, 1982·European Journal of Clinical Pharmacology·A J WilenskyS P Kaluzny
Dec 1, 1956·Proceedings of the Society for Experimental Biology and Medicine·T C BUTLER, W J WADDELL
Dec 1, 1963·Epilepsia·O SVENSMARK, F BUCHTHAL
Jul 28, 1964·Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie·H REMMER, M SIEGERT


Apr 29, 1998·Journal of Clinical Pharmacology·T R Browne
Jan 1, 1990·Journal of Pharmaceutical and Biomedical Analysis·W H SoineJ H Wood
Jan 10, 2002·Journal of Pharmaceutical Sciences·Patrick Poulin, Frank-Peter Theil
Nov 9, 2011·Advanced Drug Delivery Reviews·Cecilie Johannessen LandmarkTorbjörn Tomson
Dec 1, 1987·Journal of Veterinary Pharmacology and Therapeutics·W R RavisJ Schumacher
Jul 1, 1986·Journal of Clinical Pharmacology·T R Browne
Jul 1, 1986·Journal of Clinical Pharmacology·T R BrowneG E Schumacher
Jan 1, 1985·Journal of Clinical Pharmacology·T R BrowneG E Schumacher
May 1, 1985·Journal of Clinical Pharmacology·J E EvansD J Greenblatt
Jun 7, 2002·AAPS PharmSci·Patrick J McNamara, Jane Alcorn
Jan 1, 1985·Journal of Clinical Pharmacology·T R BrowneD J Greenblatt
Mar 1, 2002·Biopharmaceutics & Drug Disposition·A MirfazaelianM Mahmoudian
Mar 11, 2020·Frontiers in Veterinary Science·Liana M YatesMunashe Chigerwe

Related Concepts

Carbon Isotopes
Dose-Response Relationship, Drug
Chromatography, Gas-Liquid-Mass Spectrometry
Nitrogen Isotopes
Cigar smoker

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, as well as fevers and skin rashes. Here is the latest research on this disease.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.


Trichotillomania is an impulse control disorder characterized by the recurrent pulling of one's hair resulting in noticeable hair loss. Here are the latest discoveries in this field.

DDX3X Syndrome

DDX3X syndrome is caused by a spontaneous mutation at conception that primarily affects females due to its location on the X-chromosome. DDX3X syndrome has been linked to intellectual disabilities, seizures, autism, low muscle tone, brain abnormalities, and slower physical developments. Here is the latest research.